Personalis Q2 revenue rises 30%, beats estimates on expanded Medicare coverage

Personalis

04/08/2026 21:13

Overview
US genomics firm's Q2 revenue rose 30% yr/yr, beating analyst expectations
Clinical test volume and clinical revenue surged on expanded Medicare coverage
Company will not provide financial guidance due to pending Tempus AI merger

Outlook
Personalis will no longer provide financial guidance due to pending merger with Tempus AI
Company expects more than a 500% increase in clinical revenue over last year
Personalis expects continued growth in NeXT Personal adoption and reimbursement expansion

Result Drivers
EXPANDED MEDICARE COVERAGE - Co said clinical revenue growth was driven by expanded Medicare coverage for NeXT Personal, including new approvals for immunotherapy and breast cancer monitoring
CLINICAL TEST VOLUME - Clinical test volume surged 199% yr/yr and 33% sequentially to 10,384 tests, supporting higher clinical revenue
PHARMA TESTING SERVICES - Revenue from pharma testing services and all other customers rose 51% yr/yr to $16.8 mln

Company press release: ID:nBwPLKk7a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$22.36 mln
$16.78 mln (6 Analysts)
Q2 Net Loss
 
$31.68 mln
 
Q2 Income From Operations
 
-$33.59 mln
 
Q2 Loss Per Basic Share
 
$0.30
 
Q2 Pretax Loss
 
$31.68 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Personalis, Inc. is $16.25, about 23.1% above its August 3 closing price of $13.20

Reuters Recommended Reads
Aug 3 - GeneDx Q2 revenue beats analyst estimates
Aug 4 - Switzerland's SOPHiA GENETICS Q2 revenue rises on Liquid Biopsy growth
Aug 4 - Revvity raises annual profit, revenue forecasts on strong diagnostics demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)